| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | BCW2; SMIT; SMIT1; SMIT2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human SLC5A3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC5A3抗体的3-4篇文献示例(文献信息为虚构，仅作格式参考)：
1. **文献名称**: "SLC5A3 expression in cerebellar development and related neurodevelopmental disorders"
**作者**: Zhang L, et al. (2015)
**摘要**: 通过免疫组化和小鼠模型，利用SLC5A3抗体证实其在胚胎期小脑高表达，并提示其缺失可能与神经发育异常相关。
2. **文献名称**: "SLC5A3 as a potential biomarker in glioblastoma: Antibody-based validation"
**作者**: Smith J, et al. (2018)
**摘要**: 使用SLC5A3单克隆抗体进行Western blot和免疫荧光分析，发现胶质母细胞瘤中SLC5A3蛋白表达显著上调，与患者生存率负相关。
3. **文献名称**: "Functional characterization of SLC5A3 knockout cells using specific antibody targeting"
**作者**: Tanaka K, et al. (2020)
**摘要**: 通过CRISPR-Cas9构建SLC5A3敲除细胞系，结合抗体验证蛋白缺失，揭示其在细胞渗透压调节和应激反应中的作用。
4. **文献名称**: "SLC5A3 antibody-based profiling in colorectal cancer tissues"
**作者**: Müller R, et al. (2021)
**摘要**: 利用SLC5A3多克隆抗体对结直肠癌组织进行免疫组化分析，发现其表达水平与肿瘤转移和化疗耐药性相关。
(注：以上文献为示例，实际文献需通过PubMed/Google Scholar等平台以“SLC5A3 antibody”为关键词检索。)
The SLC5A3 antibody targets the solute carrier family 5 member 3 (SLC5A3), a sodium-dependent myo-inositol transporter encoded in humans by the *SLC5A3* gene. This protein plays a critical role in cellular osmoregulation and neurological function by transporting myo-inositol, a cyclic polyol essential for cell signaling and osmoprotection, into cells. SLC5A3 is highly expressed in the brain, kidneys, and placenta, where it maintains inositol homeostasis, particularly under hypertonic stress. Dysregulation of SLC5A3 has been implicated in neurological disorders such as epilepsy, Alzheimer’s disease, and rare genetic conditions like SMIT1 deficiency syndrome, characterized by developmental delays and seizures.
Antibodies against SLC5A3 are vital tools for studying its expression, localization, and functional roles in both physiological and pathological contexts. They enable techniques like immunohistochemistry, Western blotting, and immunofluorescence to visualize protein distribution in tissues or assess expression levels in disease models. Researchers also use these antibodies to explore SLC5A3’s interaction with signaling pathways, such as the phosphatidylinositol (PI) cycle, and its potential as a therapeutic target for osmotic imbalance-related disorders.
Commercial SLC5A3 antibodies are typically validated for specificity in human, mouse, or rat samples. However, variability in antibody performance across species or experimental conditions requires careful validation. Ongoing research aims to clarify SLC5A3’s role in cellular stress responses and neurodegeneration, underscoring its relevance in translational neuroscience.
×
